The burden cost of French patients suffering from irritable bowel syndrome

References

• Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:3–15.
   PubMed Web of Science ®Google Scholar
• Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002;122:1701–14.
   PubMed Web of Science ®Google Scholar
• Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al. British Society of Gastroenterology guidelines for themanagement of the irritable bowel syndrome. Gut2000;47 Suppl II:ii1–19.
   Google Scholar
• Kay L, Jorgensen T, Jensen KH. The epidemiology of irritable bowel syndrome in a random population: prevalence, incidence, natural history and risk factors. J Intern Med 1994;236:23–30.
   Google Scholar
• Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional Gastrointestinal disorders in Canada. First population based survey using Rome II criteria with suggestions for improving the questionnaire. Digest Dis Sci 2002;47:225–35.
   Google Scholar
• Mearin F, Badia X, Balboa A, Baro E, Caldwell E, Cucala M, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria in a general population. Scand J Gastroenterol 2001;11:1155–61.
   Google Scholar
• Manning AP, Thompson WG, Heaton KW, Morris AF. Toward positive diagnosis of irritable bowel. Br Med J 1978;2:653–54.
   PubMed Web of Science ®Google Scholar
• Müller-Lissner SA, Bollani S, Brummer RJ, Coremans G, Dapoigny M, Marshall JK, et al. Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 2001;64:200–4.
   Google Scholar
• Drossman DA, Li Z, Andruzzi E, Temple R, Talley NJ, Thompson WG, et al. US householder survey of functional gastrointestinal disorders: prevalence, socio-demography and health impact. Dig Dis Sci 1993;38:1569–80.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Richter JE, Talley NJ, Thompson WG, Corazziari E, Whitehead WE (eds). The functional gastrointestinal disorders. Boston: Little Brown; 1994.
   Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain, Gut 1999;45 Suppl 2:II43–II7.
   Google Scholar
• Bommelaer G, Dorval E, Denis P, Czernichow P, Frexinos J, Pelc A, et al. Prevalence of irritable bowel syndrome according to the Rome criteria in the French population. Gastroenterology 2000;118 Suppl 2:A3, 950.
   Google Scholar
• Dapoigny M, Bellanger J, Bonaz B, Bruley de Varannes S, Bueno L, et al. Syndrome de l’intestin irritable (SII) en France: une pathologie invalidante et coûteuse. Gastroenterol Clin Biol 2002;26:A121.
   Google Scholar
• Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice. Am J Gastroenterol 2000;95:3176–83.
   Google Scholar
• Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton J. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000;95:2816–24.
   PubMed Web of Science ®Google Scholar
• Delvaux M, Frexinos J. A European approach to irritable bowel syndrome management. Can J Gastroenterol 1999;Suppl A:85A–8A.
   Google Scholar
• Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut 1997;41:394–98.
   Google Scholar
• Talley NJ, Zinsmeister AR, Melton LJ, III. Irritable bowel syndrome in a community: symptoms, subgroups, risk factors, and health care utilization. Am J Epidemiol 1995;142:76–83.
   PubMed Web of Science ®Google Scholar
• Heaton KW, O’Donnell LJ, Braddon FE, Mountford RA, Hughes AO, Cripps PJ. Symptoms of irritable bowel syndrome in a British urban community: consulters and non-consulters. Gastroenterology 1992;102:1962–7.
   PubMed Web of Science ®Google Scholar
• Bommelaer G, Rouch M, Dapoigny M, Pais D, Loisy P, Gualino M, et al. Epidemiologie des troubles fonctionnels intestinaux dans une population apparemment saine. Gastroenterol Clin Biol 1986;10:7–12.
   PubMedGoogle Scholar
• Hahn BA, Yan S, Strassels S. Impact ofirritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999;60:77–81.
   Google Scholar
• Akehurst RL, Brazier JE, Mathers N, O’Keefe C, Kaltenthaler E, Morgan A, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002;20:455–62.
   Google Scholar
• Wells NEJ, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11:1019–30.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Williams DE. Economic burden of irritable bowel syndrome—proposed strategies to control expenditures. Pharmacoeconomics 2000;17:331–8.
   PubMed Web of Science ®Google Scholar
• CRAM Ilde-de-France. Indicateur Statistique, 1998–1999 edition.
   Google Scholar
• Bommelaer G, Poynard T, Le Pen C, Gaudin A-F, Maurel F, Priol G, et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol. In press.
   Google Scholar
• Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies. Pharmacoeconomics 1999;15:241–56.
   PubMed Web of Science ®Google Scholar
• Danquechin Dorval E, Delvaux M, Allemand H, Allouche S, Van Egroo LD, Le Pen C. Profil and evolution of irritable bowel syndrome. Prospective national epidemiological study of 1301 patients followed-up for 9 months in gastroenterology. Groupe d’étude Nationale sur le Syndrome de l’Intestin irritable (SII). Gastroenterol Clin Biol 1994;18:145–50.
   Google Scholar
• Talley NJ, Gabriel SE, Harmesen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736–41.
   Google Scholar
• Badia X, Mearin F, Balboa A, Baro E, Caldwell E, Cucala M, et al. Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics 2002;20:749–58.
   PubMed Web of Science ®Google Scholar